Helbig, Linda <br/><br/>
BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts.  [electronic resource] 

 -  Radiation oncology (London, England)  Sep 2014 
 - 207 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1748-717X 
<br/><br/><label>Standard No.: </label>10.1186/1748-717X-9-207  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Blotting, Western<br/>Carcinoma, Squamous Cell--pathology<br/>Cell Hypoxia--drug effects<br/>Chemoradiotherapy--methods<br/>Dose Fractionation, Radiation<br/>Head and Neck Neoplasms--pathology<br/>Humans<br/>Hypoxia-Inducible Factor 1, alpha Subunit--antagonists & inhibitors<br/>Mice<br/>Mice, Nude<br/>Oxadiazoles--pharmacology<br/>Pyrazoles--pharmacology<br/>Radiation-Sensitizing Agents--pharmacology<br/>Squamous Cell Carcinoma of Head and Neck<br/>Xenograft Model Antitumor Assays